Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antibiotics for the treatment of COVID-19.
Popp M, Stegemann M, Riemer M, Metzendorf MI, Romero CS, Mikolajewska A, Kranke P, Meybohm P, Skoetz N, Weibel S. Popp M, et al. Among authors: skoetz n. Emergencias. 2023 Oct;35(5):378-380. Emergencias. 2023. PMID: 37801419 English, Spanish. No abstract available.
Colchicine for the treatment of COVID-19.
Mikolajewska A, Fischer AL, Piechotta V, Mueller A, Metzendorf MI, Becker M, Dorando E, Pacheco RL, Martimbianco ALC, Riera R, Skoetz N, Stegemann M. Mikolajewska A, et al. Among authors: skoetz n. Emergencias. 2023 Aug;35(4):300-302. Emergencias. 2023. PMID: 37439424 English, Spanish. No abstract available.
Ivermectin for preventing and treating COVID-19.
Popp M, Reis S, Schießer S, Ilona Hausinger R, Stegemann M, Metzendorf MI, Kranke P, Meybohm P, Skoetz N, Weibel S. Popp M, et al. Among authors: skoetz n. Emergencias. 2023 Oct;35(5):381-383. Emergencias. 2023. PMID: 37801420 English, Spanish. No abstract available.
Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS‑CoV‑2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort.
Shi Y, Strobl R, Apfelbacher C, Bahmer T, Geisler R, Heuschmann P, Horn A, Hoven H, Keil T, Krawczak M, Krist L, Lemhöfer C, Lieb W, Lorenz-Depiereux B, Mikolajczyk R, Montellano FA, Reese JP, Schreiber S, Skoetz N, Störk S, Vehreschild JJ, Witzenrath M, Grill E; NAPKON Study Group. Shi Y, et al. Among authors: skoetz n. Infection. 2023 Dec;51(6):1679-1694. doi: 10.1007/s15010-023-02043-6. Epub 2023 May 25. Infection. 2023. PMID: 37231313 Free PMC article.
GRADE concept paper 8: judging the certainty of discrimination performance estimates of prognostic models in a body of validation studies.
Foroutan F, Mayer M, Guyatt G, Riley RD, Mustafa R, Kreuzberger N, Skoetz N, Darzi A, Alba AC, Mowbray F, Rayner DG, Schunemann H, Iorio A. Foroutan F, et al. Among authors: skoetz n. J Clin Epidemiol. 2024 Apr 3;170:111344. doi: 10.1016/j.jclinepi.2024.111344. Online ahead of print. J Clin Epidemiol. 2024. PMID: 38579978 Free article.
Patient-reported outcomes in Hodgkin lymphoma trials: a systematic review.
Oliva EN, Ionova T, Laane E, Csenar M, Schroer J, Behringer K, Monsef I, Oeser A, Skoetz N, Salek S. Oliva EN, et al. Among authors: skoetz n. Front Oncol. 2024 Mar 13;14:1353101. doi: 10.3389/fonc.2024.1353101. eCollection 2024. Front Oncol. 2024. PMID: 38544841 Free PMC article.
177 results